Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer pp 154–172Cite as

Endocrine and Cytotoxic Therapy

  • Chapter

Abstract

A disease common enough to account for 6% of all malignant disease in the male inevitably merits serious consideration and committed research programmes. The full impact of prostatic cancer is to some extent reduced for three reasons: the diagnosis is made in over 50% of patients after the age of 65; there is a known incidence of 20%–50% of latent cancer (Wynder et al. 1971); and approximately two-thirds of patients die of some other condition (Byar 1973).

I should like to acknowledge my thanks to Miss S. A. Barrowby for her help in the preparation of this paper

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Beckley S, Wajsman Z, Slack N, Mittelman A, Murphy GP (to be published) The chemotherapy of prostatic carcinoma. Scand J Urol Nephrol Blackard CE, Mellinger GT, Gleason DF (1971) Treatment of stage 1 carcinoma of the prostate. A preliminary report. J Urol 106: 729–733

    Google Scholar 

  • Byar DP (1973) The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 32: 1126–1130

    Article  PubMed  CAS  Google Scholar 

  • Byar DP (1980) Review of the Veterans Administration studies of cancer of the prostate and new results concerning treatment of stage I and II tumours. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumours and other topics in urological oncology. Plenum Press, New York London, pp 471–492

    Google Scholar 

  • Byar DP, Veterans Administration Cooperative Urological Research Group (1972) Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol 108: 908–913

    PubMed  CAS  Google Scholar 

  • Carter SK, Wasserman TH (1975) The chemotherapy of urologie cancer. Cancer 36: 729–747

    Article  PubMed  CAS  Google Scholar 

  • Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cylophosphamide in the treatment of metastatic prostatic cancer. A randomised trial. Cancer 42: 2546–2552

    Article  PubMed  CAS  Google Scholar 

  • Corder MP, Cicmil GA (1976) Effective treatment of metastatic squamous carcinoma of the prostate with adriamycin. J Urol 115: 222

    PubMed  CAS  Google Scholar 

  • Correa RJ Jr, Anderson RG, Gibbons RP, Mason JT (1974) Latent carcinoma of the prostate — why the controversy? J Urol 111: 644–646

    PubMed  Google Scholar 

  • De Wys WD (1975) Comparison of adriamycin (NSC 123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer. Cancer Chemother Rep 59: 215–217

    Google Scholar 

  • De Wys WD, Bauer M, Colsky J, Cooper RA, Creech R, Carbone PP (1977) Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer. Progress report. Cancer Treat Rep 61: 325–328

    Google Scholar 

  • Donohue RE, Fauver HE, Whitesel JA, Pfister RR (1979) Staging prostatic cancer: a different distribution. J Urol 122: 327–329

    PubMed  CAS  Google Scholar 

  • Eagan RT, Hahn RG, Myers RP (1976) Adriamycin versus 5FU and cyclophosphamide in the treatment of metastatic prostatic cancer. Cancer Treat Rep 60: 115–117

    PubMed  CAS  Google Scholar 

  • Franks CR (1979) Melphalan in metastatic cancer of the prostate. Cancer Treat Rev [Suppl] 6: 121–125

    Article  PubMed  Google Scholar 

  • Houghton AL, Robinson MRG, Smith PH (1977) Melphalan in advanced prostatic cancer. A pilot study. Cancer Chemother Rep 61: 923–924

    CAS  Google Scholar 

  • Huggins C, Hodges CV (1941) Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297

    CAS  Google Scholar 

  • Izbicki RM, Amer MH, Al-Sarraf M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: A phase II study. Cancer Treat Rep 63: 999–1001

    PubMed  CAS  Google Scholar 

  • Johnson DE, Scott WW, Gibbons RP, Prout GR Jr, Schmidt JD, Chu TM, Gaeta J, Saroff J, Murphy GP (1977) National randomised study of chemotherapeutic agents in advanced prostatic cancer. A progress report. Cancer Treat Rep 61: 317–323

    PubMed  CAS  Google Scholar 

  • Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411–1413

    PubMed  Google Scholar 

  • Kane RD, Stocks LH, Paulson DF (1977) Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: A preliminary report. J Urol 117: 467–471

    PubMed  CAS  Google Scholar 

  • Khan R, Turner B, Edson M, Dolan M (1977) Bone marrow acid phosphatase: Another look. J Urol 117: 79–80

    PubMed  CAS  Google Scholar 

  • Kliman B, Prout GR Jr, Maclaughlin RA, Daly JJ, Griffin PP (1978) Altered androgen metabolism in metastatic prostate cancer. J Urol 119: 623–626

    PubMed  CAS  Google Scholar 

  • Kvols LK, Eagan RT, Myers RP (1977) Evaluation of melphalan, ICRF-159 and hydroxyurea in metastatic prostatic cancer: A preliminary report. Cancer Treat Rep 61: 311–312

    PubMed  CAS  Google Scholar 

  • Lerner H, Malloy T, Cromie W, Longo S (1975) Hydroxyurea in stage D carcinoma of the prostate. A pilot study. J Urol 114: 425–429

    PubMed  CAS  Google Scholar 

  • Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon LJ (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: A phase II trial. Cancer Treat Rep 60: 77–83

    PubMed  CAS  Google Scholar 

  • Menon M, Walsh PC (1979) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer. P.S.G., Littleton, pp 175–200

    Google Scholar 

  • Merrin CE (1979) Treatment of genitourinary tumors with cis-dichlorodiammineplatinum. II. Experience in 250 patients. Cancer Treat Rep 63: 1579–1584

    PubMed  CAS  Google Scholar 

  • Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J Urol 115: 86–88

    PubMed  CAS  Google Scholar 

  • Murphy GP, Gibbons RP, Johnson DE, Loening SA, Prout GR, Schmidt JD, Bross DS, Chu TM, Gaeta JF, Saroff J, Scott, WW (1977) A Comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 118: 288–291

    PubMed  CAS  Google Scholar 

  • Murphy GP, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Soloway MS, Loening SA, Chu TM, Gaeta JF, Saroff J, Wajsman Z, Slack N, Scott WW (1979) The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. J Urol 121: 763–765

    PubMed  CAS  Google Scholar 

  • Paulson DF, Berry WR, Cox EB, Walker A, Laszlo J (1979) Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: Indicators of response to therapy. J Natl Cancer Inst 63: 615–622

    PubMed  CAS  Google Scholar 

  • Robinson MRG, Thomas BG (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391–394

    Article  PubMed  CAS  Google Scholar 

  • Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C Jr, Eyre, HJ, Fisher R (1979) Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group study. Cancer Treat Rep 63: 1557–1564

    PubMed  CAS  Google Scholar 

  • Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR Jr, Loening SA, Soloway MS, Chu TM, Gaeta JF, Slack NH, Saroff J, Murphy GP (1979) Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121: 185–189

    PubMed  CAS  Google Scholar 

  • Scott WW, Johnson DE, Schmidt JE, Gibbons RP, Prout GR, Joiner JR, Saroff J, Murphy GP (1975) Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: Results of the First National Randomized Study. J Urol 114: 909–911

    PubMed  CAS  Google Scholar 

  • Silverberg GD (1977) Hypophysectomy in the Treatment of Disseminated Prostate Carcinoma. Cancer 39: 1727–1731

    Article  PubMed  CAS  Google Scholar 

  • Smith PH (to be published) The medical management of prostatic cancer — some current questions. Eur Urol

    Google Scholar 

  • Soloway MS, Shippel RM, Ikard M (1979) Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 122: 637–639

    PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017

    Google Scholar 

  • Wynder El, Mabuchi K, Whitmore WF Jr (1971) Epidemiology of cancer of the prostate. Cancer 28: 344–360

    Article  PubMed  CAS  Google Scholar 

  • Yagoda A (1979) Phase II trials with cis-dichlorodiammineplatinum (II) in the treatment of urothelial cancer. Cancer Treat Rep 63: 1565–1572

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, St. James’s University Hospital, GB - Leeds, UK

    P. H. Smith

Authors
  1. P. H. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Western General Hospital and Royal Infirmary, Grewe Road, Edinburgh, EH4 2XU, UK

    William Duncan

Rights and permissions

Reprints and permissions

Copyright information

© 1981 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Smith, P.H. (1981). Endocrine and Cytotoxic Therapy. In: Duncan, W. (eds) Prostate Cancer. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 78. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81621-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81621-5_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81623-9

  • Online ISBN: 978-3-642-81621-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation